Nasdaq
$20.77▲ 1.61%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.24BShares out 59.5M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
15- 9.21After-hours26.09.22 06:21SCHEDULE 13GOwnership#●●●#●●●
Tyra Biosciences, Inc.
Biotechnology Value Fund and its affiliated investment entities have filed a Schedule 13G regarding their ownership of Tyra Biosciences, Inc. common stock. This filing is made pursuant to a joint filing agreement dated September 21, 2026.…more
$20.77+1.61%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.17After-hours26.09.18 08:294Ownership
Tyra Biosciences, Inc.
Insider Todd Harris of Tyra Biosciences, Inc. reported a change in beneficial ownership of company securities as of September 15, 2026. This filing serves as a standard Form 4 notification regarding the executive's stock holdings.…more
$20.77+1.61%vs prev closeView filingShare - 9.17After-hours26.09.18 08:264Ownership
Tyra Biosciences, Inc.
Insider Yuliya Rueb of Tyra Biosciences, Inc. filed a Form 4 report regarding changes in beneficial ownership of securities as of September 15, 2026. This filing serves as a routine disclosure of executive stock holdings.…more
$20.77+1.61%vs prev closeView filingShare
14 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.14Pre-market26.09.14 19:49Bullish#●●●#●●●#●●●
Tyra Biosciences Prices $400 Million Public Offering
Tyra Biosciences has priced an underwritten offering of common stock and pre-funded warrants to raise approximately $400 million in gross proceeds. The company plans to use the net proceeds to advance its clinical development programs and for general corporate purposes.…more
$20.77+1.61%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.14Pre-market26.09.14 19:15
●●●●●●●● ●●●●● ●●●●●●
Tyra Biosciences has filed a shelf registration statement to offer various securities from time to time. This procedural move enables future capital raising, which could lead to potential shareholder dilution.…more
$20.77+1.61%vs prev closeShareBenzinga - 9.9Pre-market26.09.09 20:16
●●●●●●●● ●●●●● ●●●●●●
Tyra Biosciences announced that its Phase 2 study of oral dabogratinib showed a 79% objective response rate in patients with low-grade NMIBC. Based on these results, the company has identified 60 mg as the dose for its upcoming Phase 3 adjuvant study.…more
$20.77+1.61%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report